Ossato, A.; Gasperoni, L.; Del Bono, L.; Messori, A.; Damuzzo, V.
Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival. Cancers 2024, 16, 557.
https://doi.org/10.3390/cancers16030557
AMA Style
Ossato A, Gasperoni L, Del Bono L, Messori A, Damuzzo V.
Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival. Cancers. 2024; 16(3):557.
https://doi.org/10.3390/cancers16030557
Chicago/Turabian Style
Ossato, Andrea, Lorenzo Gasperoni, Luna Del Bono, Andrea Messori, and Vera Damuzzo.
2024. "Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival" Cancers 16, no. 3: 557.
https://doi.org/10.3390/cancers16030557
APA Style
Ossato, A., Gasperoni, L., Del Bono, L., Messori, A., & Damuzzo, V.
(2024). Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival. Cancers, 16(3), 557.
https://doi.org/10.3390/cancers16030557